Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama, 323(18), 1824-1836.
doi:10.1001/jama.2020.6019
https://jamanetwork.com/journals/jama/fullarticle/2764727/

Smith College

University of Virginia, Charlottesville

- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

JAMA articles about treatment interventions of COVID-19

Rosenberg, E., Dufort, E., Udo, T., Wilberschied, L., Kumar, J., & Tesoriero, J. et al. (2020). Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. doi: 10.1001/jama.2020.8630

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Spinner, C. D., Gottlieb, R. L., Criner, G. J., López, J. R. A., Cattelan, A. M., Viladomiu, A. S., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., Chai, L. Y. A., Roestenberg, M., Tsang, O. T. Y., Bernasconi, E., Turnier, P. L., Chang, S.-C., SenGupta, D., Hyland, R. H., Osinusi, A. O., … Marty, F. M. (2020). Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2020.16349


Learn Before

Related

Related